France
BIOBank S.A., founded in 2003, is at the forefront of the Biotechnology industry, specializing in high-quality bone allografts for surgical applications, including orthopaedics, maxillofacial, and dental surgery. With its headquarters in France, the company has solidified its leadership by offering innovative solutions to health professionals.
The company's value proposition is encapsulated in its slogan, "L'os humain préservé et régénéré," highlighting its commitment to bone preservation and regeneration. Utilizing its unique Supercrit® technology, BIOBank ensures total viral inactivation while maintaining the biomechanical and structural integrity of tissues. This technology allows the production of grafts in various shapes and forms, facilitating ease of use during surgical procedures and promoting high-quality bone integration for improved patient recovery.
Strategically, BIOBank has demonstrated robust growth and innovation support, evidenced by a recent Private Equity Round on May 29, 2024, led by IK Partners. This investment positions the company to advance its technological capabilities and expand its market reach.
